A: Current trial data suggests orforglipron may produce around 9% to 10% body weight reduction in some populations, while injectable semaglutide has shown higher average weight-loss outcomes in longer trials
doi: 10.3389/fendo.2018.00672 [DOI] [PMC free article] [PubMed] [Google Scholar] 27.Bray JJH, Foster-Davies H, Salem A, et al
If semaglutide could prevent cirrhosis from developing, he says, it could halt the harmful symptoms that can accompany it, like your legs swelling up so much you cant tie your shoes, getting short of breath, vomiting blood, passing blood in your stools and developing cancer, he says
I would like people to know that microdosing is not the normal way these medications are used, though it may be feasible in those who have achieved the desired results or have much less weight to lose, Ali added
Nausea, vomiting, constipation, and gastroparesis symptoms affect 10 to 44% of patients during dose escalation [6]
Although noticeable progress may come in 6 weeks, research shows better weight loss effects in the long term